Biography

Sean Wuxiong Cao, Ph.D. was appointed as an independent director in May 2025 and subsequently became a director in September 2025 following his appointment as Chief Business Development Officer. Dr. Cao previously served as Chief Business Officer of our company during its founding days, from 2016 to 2018. Additionally, Dr. Cao co-founded Visara, Inc., the first spoke of NovaBridge. Dr. Cao has served as an operating partner of CBC Group (previously known as C-Bridge Capital) since January 2024, and as Chief Executive Officer of MLAB Biosciences, one of CBC Group’s portfolio companies, since 2022. Dr. Cao co-founded ABio-X Holdings, Inc. and has served as a director since 2021, as well as Interim Chief Executive Officer between May 2021 and November 2022, and Chief Executive Officer since September 2023. He also co-founded and served as Chief Executive Officer of Ensem Therapeutics from May 2021 to 2022. Dr. Cao co-founded and served on the board of directors of RVAC Medicines from June 2021 to June 2023. He also co-founded Jadeite Medicines and served as a director until June 2023. Dr. Cao incubated NiKang Therapeutics with its scientific co-founders in the United States, where he served as Chief Executive Officer from inception until 2020, and as chairman of its board of directors until September 2021. Before originally joining our company in 2016, Dr. Cao served as Vice President of Global Business Development at Simcere Pharmaceutical Group (HKEX: 2096) from November 2015 to September 2016. Prior to that, from March 2010 to November 2015, Dr. Cao served as Director of Alternative Partnership, Evaluation & Expertise at Sanofi (Nasdaq: SNY). Before joining Sanofi, Dr. Cao was an associate at New Leaf Venture Partners. From May 2005 to August 2008, Dr. Cao worked in the pharmaceutical and diagnostic industries, including at Johnson & Johnson (NYSE: JNJ). In 2017, Dr. Cao was appointed as a director of Everest Medicines Limited (HKEX: 1952) and subsequently served as an executive director until 2020. He has also served as a director of Paremina, Inc. since January 2024. Dr. Cao earned a Ph.D. in Microbiology from the University of Virginia, an MBA with honors from the Wharton School of the University of Pennsylvania, and a Bachelor’s in Microbiology from Nankai University.